Minimally invasive vs. open segmental resection of the splenic flexure for cancer: a nationwide study of the Italian Society of Surgical Oncology-Colorectal Cancer Network (SICO-CNN).
Colon cancer
Laparoscopic resection
Minimally invasive surgery
Open surgery
Segmental resection
Splenic flexure cancer
Journal
Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
26
03
2022
accepted:
07
08
2022
pubmed:
11
9
2022
medline:
25
2
2023
entrez:
10
9
2022
Statut:
ppublish
Résumé
Evidence on the efficacy of minimally invasive (MI) segmental resection of splenic flexure cancer (SFC) is not available, mostly due to the rarity of this tumor. This study aimed to determine the survival outcomes of MI and open treatment, and to investigate whether MI is noninferior to open procedure regarding short-term outcomes. This nationwide retrospective cohort study included all consecutive SFC segmental resections performed in 30 referral centers between 2006 and 2016. The primary endpoint assessing efficacy was the overall survival (OS). The secondary endpoints included cancer-specific mortality (CSM), recurrence rate (RR), short-term clinical outcomes (a composite of Clavien-Dindo > 2 complications and 30-day mortality), and pathological outcomes (a composite of lymph nodes removed ≧12, and proximal and distal free resection margins length ≧ 5 cm). For these composites, a 6% noninferiority margin was chosen based on clinical relevance estimate. A total of 606 patients underwent either an open (208, 34.3%) or a MI (398, 65.7%) SFC segmental resection. At univariable analysis, OS and CSM were improved in the MI group (log-rank test p = 0.004 and Gray's tests p = 0.004, respectively), while recurrences were comparable (Gray's tests p = 0.434). Cox multivariable analysis did not support that OS and CSM were better in the MI group (p = 0.109 and p = 0.163, respectively). Successful pathological outcome, observed in 53.2% of open and 58.3% of MI resections, supported noninferiority (difference 5.1%; 1-sided 95%CI - 4.7% to ∞). Successful short-term clinical outcome was documented in 93.3% of Open and 93.0% of MI procedures, and supported noninferiority as well (difference - 0.3%; 1-sided 95%CI - 5.0% to ∞). Among patients with SFC, the minimally invasive approach met the criterion for noninferiority for postoperative complications and pathological outcomes, and was found to provide results of OS, CSM, and RR comparable to those of open resection.
Sections du résumé
BACKGROUND
Evidence on the efficacy of minimally invasive (MI) segmental resection of splenic flexure cancer (SFC) is not available, mostly due to the rarity of this tumor. This study aimed to determine the survival outcomes of MI and open treatment, and to investigate whether MI is noninferior to open procedure regarding short-term outcomes.
METHODS
This nationwide retrospective cohort study included all consecutive SFC segmental resections performed in 30 referral centers between 2006 and 2016. The primary endpoint assessing efficacy was the overall survival (OS). The secondary endpoints included cancer-specific mortality (CSM), recurrence rate (RR), short-term clinical outcomes (a composite of Clavien-Dindo > 2 complications and 30-day mortality), and pathological outcomes (a composite of lymph nodes removed ≧12, and proximal and distal free resection margins length ≧ 5 cm). For these composites, a 6% noninferiority margin was chosen based on clinical relevance estimate.
RESULTS
A total of 606 patients underwent either an open (208, 34.3%) or a MI (398, 65.7%) SFC segmental resection. At univariable analysis, OS and CSM were improved in the MI group (log-rank test p = 0.004 and Gray's tests p = 0.004, respectively), while recurrences were comparable (Gray's tests p = 0.434). Cox multivariable analysis did not support that OS and CSM were better in the MI group (p = 0.109 and p = 0.163, respectively). Successful pathological outcome, observed in 53.2% of open and 58.3% of MI resections, supported noninferiority (difference 5.1%; 1-sided 95%CI - 4.7% to ∞). Successful short-term clinical outcome was documented in 93.3% of Open and 93.0% of MI procedures, and supported noninferiority as well (difference - 0.3%; 1-sided 95%CI - 5.0% to ∞).
CONCLUSIONS
Among patients with SFC, the minimally invasive approach met the criterion for noninferiority for postoperative complications and pathological outcomes, and was found to provide results of OS, CSM, and RR comparable to those of open resection.
Identifiants
pubmed: 36085382
doi: 10.1007/s00464-022-09547-6
pii: 10.1007/s00464-022-09547-6
pmc: PMC9944710
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
977-988Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
Br J Cancer. 2012 May 22;106(11):1875-80
pubmed: 22555397
Ann Oncol. 2020 Oct;31(10):1291-1305
pubmed: 32702383
Updates Surg. 2021 Apr;73(2):627-637
pubmed: 33417186
Surg Today. 2001;31(3):204-9
pubmed: 11318121
Surg Endosc. 2012 Mar;26(3):732-7
pubmed: 22038161
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Minerva Chir. 2019 Apr;74(2):176-186
pubmed: 30037179
Surg Endosc. 2020 Sep;34(9):4200-4205
pubmed: 32399939
World J Surg. 2018 Oct;42(10):3381-3389
pubmed: 29556881
Cancer Res Treat. 2010 Jun;42(2):69-76
pubmed: 20622960
Surg Endosc. 2017 Jun;31(6):2607-2615
pubmed: 27734203
J Gastrointest Surg. 2012 Jul;16(7):1379-88
pubmed: 22585532
Am J Surg. 2018 Aug;216(2):251-254
pubmed: 28709626
Colorectal Dis. 2013 Feb;15(2):e79-83
pubmed: 23078032
World J Surg. 2019 Mar;43(3):659-695
pubmed: 30426190
J Natl Cancer Inst. 2013 Aug 7;105(15):1151-6
pubmed: 23878352
N Engl J Med. 2004 May 13;350(20):2050-9
pubmed: 15141043
Br J Surg. 1986 Aug;73(8):663-70
pubmed: 3742184
Surg Endosc. 2005 Jan;19(1):55-9
pubmed: 15531967
Colorectal Dis. 2015 Jul;17(7):635-41
pubmed: 25580874
Surg Endosc. 2010 Nov;24(11):2749-54
pubmed: 20383534
Br J Surg. 2013 Jan;100(1):75-82
pubmed: 23132548
Arch Esp Urol. 2018 Jan;71(1):97-107
pubmed: 29336338
Lancet. 2002 Jun 29;359(9325):2224-9
pubmed: 12103285
J Natl Cancer Inst. 2012 Nov 7;104(21):1635-46
pubmed: 23104212
Arch Surg. 2008 Aug;143(8):762-7; discussion 768
pubmed: 18711036
Surg Innov. 2020 Apr;27(2):143-149
pubmed: 31893973
Surg Today. 2014 Nov;44(11):2045-51
pubmed: 24306213
N Engl J Med. 2018 Mar 29;378(13):1177-1188
pubmed: 29590544
Surg Endosc. 2003 Jun;17(6):972-8
pubmed: 12640542
Surgery. 2003 Sep;134(3):432-6
pubmed: 14555930
Arch Surg. 2005 Jul;140(7):692-7
pubmed: 16027336
Surg Endosc. 2017 Aug;31(8):3297-3305
pubmed: 27924392
Int J Colorectal Dis. 2016 Mar;31(3):623-30
pubmed: 26689401
Eur J Surg Oncol. 2020 Sep;46(9):1683-1688
pubmed: 32220542
J Gastrointest Surg. 2020 Oct;24(10):2389-2392
pubmed: 32583322
J Surg Oncol. 2016 Dec;114(8):1029-1030
pubmed: 27709621
Dis Colon Rectum. 2018 Apr;61(4):441-446
pubmed: 29521825
Lancet Gastroenterol Hepatol. 2017 Apr;2(4):261-268
pubmed: 28404155
Eur J Cancer. 2012 May;48(8):1235-43
pubmed: 22071131
J Nippon Med Sch. 2019 Sep 3;86(4):201-206
pubmed: 31204380
Ann Surg. 2019 Jun;269(6):1109-1116
pubmed: 31082909
J Gastroenterol. 2000;35(7):528-35
pubmed: 10905361
Lancet Oncol. 2014 Jun;15(7):767-74
pubmed: 24837215
J Gastrointest Surg. 2010 May;14(5):818-23
pubmed: 20224982
Surg Endosc. 2009 Aug;23(8):1812-7
pubmed: 19263150
Int J Colorectal Dis. 2018 Jun;33(6):709-717
pubmed: 29541894
Arch Surg. 2007 Mar;142(3):298-303
pubmed: 17372057
Lancet. 2005 May 14-20;365(9472):1718-26
pubmed: 15894098
Postgrad Med J. 1992 Jun;68(800):487
pubmed: 1437940
Dis Colon Rectum. 2020 Oct;63(10):1372-1382
pubmed: 32969880